BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38109990)

  • 21. FAT4 silencing promotes epithelial-to-mesenchymal transition and invasion via regulation of YAP and β-catenin activity in ovarian cancer.
    Malgundkar SH; Burney I; Al Moundhri M; Al Kalbani M; Lakhtakia R; Okamoto A; Tamimi Y
    BMC Cancer; 2020 May; 20(1):374. PubMed ID: 32366234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma.
    Zhai Y; Iura A; Yeasmin S; Wiese AB; Wu R; Feng Y; Fearon ER; Cho KR
    Oncogene; 2011 Oct; 30(40):4152-62. PubMed ID: 21499300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
    Shen H; Yan W; Yuan J; Wang Z; Wang C
    J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PCNP promotes ovarian cancer progression by accelerating β-catenin nuclear accumulation and triggering EMT transition.
    Dong P; Fu H; Chen L; Zhang S; Zhang X; Li H; Wu D; Ji X
    J Cell Mol Med; 2020 Jul; 24(14):8221-8235. PubMed ID: 32548978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer.
    Kwon M; Kim JH; Rybak Y; Luna A; Choi CH; Chung JY; Hewitt SM; Adem A; Tubridy E; Lin J; Libutti SK
    Oncotarget; 2016 Nov; 7(47):77052-77070. PubMed ID: 27776341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of miR-155 Ameliorates Acute Kidney Injury by Apoptosis Involving the Regulation on TCF4/Wnt/β-Catenin Pathway.
    Zhang XB; Chen X; Li DJ; Qi GN; Dai YQ; Gu J; Chen MQ; Hu S; Liu ZY; Yang ZM
    Nephron; 2019; 143(2):135-147. PubMed ID: 31216555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-canonical signaling pathway of SNAI2 induces EMT in ovarian cancer cells by suppressing miR-222-3p transcription and upregulating PDCD10.
    Fan L; Lei H; Zhang S; Peng Y; Fu C; Shu G; Yin G
    Theranostics; 2020; 10(13):5895-5913. PubMed ID: 32483426
    [No Abstract]   [Full Text] [Related]  

  • 29. BRMS1L suppresses ovarian cancer metastasis via inhibition of the β-catenin-wnt pathway.
    Cao P; Zhao S; Sun Z; Jiang N; Shang Y; Wang Y; Gu J; Li S
    Exp Cell Res; 2018 Oct; 371(1):214-221. PubMed ID: 30118697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ITF2 prevents activation of the β-catenin-TCF4 complex in colon cancer cells and levels decrease with tumor progression.
    Shin HW; Choi H; So D; Kim YI; Cho K; Chung HJ; Lee KH; Chun YS; Cho CH; Kang GH; Kim WH; Park JW
    Gastroenterology; 2014 Aug; 147(2):430-442.e8. PubMed ID: 24846398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiR-452 promotes an aggressive colorectal cancer phenotype by regulating a Wnt/β-catenin positive feedback loop.
    Li T; Jian X; He H; Lai Q; Li X; Deng D; Liu T; Zhu J; Jiao H; Ye Y; Wang S; Yang M; Zheng L; Zhou W; Ding Y
    J Exp Clin Cancer Res; 2018 Sep; 37(1):238. PubMed ID: 30253791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LncCCAT1 Promotes Breast Cancer Stem Cell Function through Activating WNT/β-catenin Signaling.
    Tang T; Guo C; Xia T; Zhang R; Zen K; Pan Y; Jin L
    Theranostics; 2019; 9(24):7384-7402. PubMed ID: 31695775
    [No Abstract]   [Full Text] [Related]  

  • 33. TET1 inhibits EMT of ovarian cancer cells through activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2.
    Duan H; Yan Z; Chen W; Wu Y; Han J; Guo H; Qiao J
    Gynecol Oncol; 2017 Nov; 147(2):408-417. PubMed ID: 28851501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KLF3 Transcription Activates WNT1 and Promotes the Growth and Metastasis of Gastric Cancer via Activation of the WNT/β-Catenin Signaling Pathway.
    Li Y; Wang Y; Zou Q; Li S; Zhang F
    Lab Invest; 2023 Jun; 103(6):100078. PubMed ID: 36827869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcription factor 4 expression and correlation with tumor progression in gallbladder cancer.
    Neogi K; Tewari M; Singh AK; Sharma K; Tej GNVC; Verma SS; Gupta SC; Nayak PK
    J Cancer Res Ther; 2022; 18(3):668-676. PubMed ID: 35900539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-6089/MYH9/β-catenin/c-Jun negative feedback loop inhibits ovarian cancer carcinogenesis and progression.
    Liu L; Ning Y; Yi J; Yuan J; Fang W; Lin Z; Zeng Z
    Biomed Pharmacother; 2020 May; 125():109865. PubMed ID: 32058212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GOLPH3 induces epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway in epithelial ovarian cancer.
    Sun J; Yang X; Zhang R; Liu S; Gan X; Xi X; Zhang Z; Feng Y; Sun Y
    Cancer Med; 2017 Apr; 6(4):834-844. PubMed ID: 28332316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-495 inhibits the progression of non-small-cell lung cancer by targeting TCF4 and inactivating Wnt/β-catenin pathway.
    Zheng HE; Wang G; Song J; Liu Y; Li YM; Du WP
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7750-7759. PubMed ID: 30536319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Jagged1 expression regulated by Notch3 and Wnt/β-catenin signaling pathways in ovarian cancer.
    Chen X; Stoeck A; Lee SJ; Shih IeM; Wang MM; Wang TL
    Oncotarget; 2010 Jul; 1(3):210-8. PubMed ID: 20953350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma.
    Xue W; Dong B; Zhao Y; Wang Y; Yang C; Xie Y; Niu Z; Zhu C
    Cell Oncol (Dordr); 2021 Dec; 44(6):1351-1361. PubMed ID: 34796468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.